Inhibitory effect and transcriptional impact of berberine and evodiamine on human white preadipocyte differentiation

Fitoterapia

Volumn 81, Issue 4, 2010, Pages 259-268

  Hu, Yueshan ^a   Fahmy, Hesham ^a   Zjawiony, Jordan K ^b   Davies, Gareth E ^a,c,d  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c Avera Health   (United States)

^d UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Berberine; Combination; Differentiation; Evodiamine; GATA; Human white preadipocyte

Indexed keywords

BERBERINE; EVODIAMINE; MESSENGER RNA; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR GATA 3; ANTIOBESITY AGENT; PLANT EXTRACT; QUINAZOLINE DERIVATIVE;

ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MONOTHERAPY; OBESITY; OPTICAL ROTATORY DISPERSION; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; RACEMIC MIXTURE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WHITE ADIPOSE TISSUE; ADIPOCYTE; CELL LINE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ADIPOCYTES; ADIPOSE TISSUE, WHITE; ANTI-OBESITY AGENTS; BERBERINE; CELL DIFFERENTIATION; CELL LINE; GATA2 TRANSCRIPTION FACTOR; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; HUMANS; PLANT EXTRACTS; QUINAZOLINES; RNA, MESSENGER; UP-REGULATION;

EID: 77950521443     PISSN: 0367326X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fitote.2009.09.012     Document Type: Article

References (44)

1. Kopelman P.G. Obesity as a medical problem. Nature 404 (2000) 635-643
2. Spiegelman B.M., and Flier J.S. Obesity and the regulation of energy balance. Cell 104 (2001) 531-543
3. Overweight, obesity, and health risk. National Task Force on the Prevention and Treatment of Obesity. Arch Intern Med 2000;160:898-904.
4. Fontaine K.R., Redden D.T., Wang C., Westfall A.O., and Allison D.B. Years of life lost due to obesity. JAMA 289 (2003) 187-193
5. Auwerx J., Martin G., Guerre-Millo M., and Staels B. Transcription, adipocyte differentiation, and obesity. J Mol Med 74 (1996) 347-352
6. Rosen E.D., Walkey C.J., Puigserver P., and Spiegelman B.M. Transcriptional regulation of adipogenesis. Genes Dev 14 (2000) 1293-1307
7. Farmer S.R. Transcriptional control of adipocyte formation. Cell Metab 4 (2006) 263-273
8. Tong Q., and Hotamisligi G.S. Molecular mechanisms of adipocyte differentiation. Rev Endocr Metab Disord 2 (2001) 349-355
9. Tong Q., Dalgin G., Xu H., Ting C.N., Leiden J.M., and Hotamisligil G.S. Function of GATA transcription factors in preadipocyte-adipocyte transition. Science 5489 (2000) 134-138
10. Tong Q., Tsai J., Tan G., Dalgin G., and Hotamisligil G.S. Interaction between GATA and the C/EBP family of transcription factors is critical in GATA-mediated suppression of adipocyte differentiation. Mol Cell Biol 25 (2005) 706-715
11. Huang K.C., and Williams W.M. Antibacterial, antiviral, and antifungal herbs. Pharmacol Chin Herbs (1999) 381-383
12. Amin A.H. Berberine sulfate: antimicrobial activity, bioassay, and mode of action. Can J Microbiol 15 (1969) 1067-1076
13. Anis K.V., Rajeshkumar N.V., and Kuttan R. Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 53 (2001) 763-768
14. Kuo C.L., Chi C.W., and Liu T.Y. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 203 (2004) 127-137
15. Kong W., Wei J., Abidi P., Lin M., Inaba S., Li C., et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10 (2004) 1344-1351
16. Zhou L.B. Effect of berberine on the differentiation of adipocyte. Zhonghua Yi Xue Za Zhi 83 (2003) 338-340
17. Huang C., Zhang Y.B., Gong Z.W., Sheng X.Y., Li Z.M., Zhang W., et al. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARγ pathway. Biochem Biophys Res Commun 348 (2006) 571-578
18. Yi P., Lu F.E., Xu L.J., Chen G., Dong H., and Wang K.F. Berberine reverses free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKβ. World J Gastroenterol 14 6 (2008) 876-883
19. Brusq J.M., Ancellin N., Grondin P., Guillard R., Martin S., Saintillan Y., et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 7 (2006) 1281-1288
20. Cheng Z., Pang T., Gu M., Gao A.H., Xie C.M., Li J.Y., et al. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim Biophys Acta 1760 (2006) 1682-1689
21. Zhou L., Yang Y., Wang X., Liu S., Shang W., Yuan G., et al. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism 56 (2007) 405-412
22. Hu Y., and Davies G.E. Berberine increases expression of GATA-2 and GATA-3 during inhibition of adipocyte differentiation. Phytomedicine 16 (2009) 864-873
23. Chiou W.F., Sung Y.J., Liao J.F., Shum A.Y., and Chen C.F. Inhibitory effect of dehydroevodiamine and evodiamine on nitric oxide production in cultured murine macrophages. J Nat Prod 60 (1997) 708-711
24. Liao C.H., Pan S.L., Guh J.H., Chang Y.L., Pai H.C., Lin C.H., et al. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis 26 (2005) 968-975
25. Tan Y.H., Wu Y.Y., Zhong F.Y., Hu Y.S., Lin Y.Z., and Li J.F. Proliferation-inhibited and apoptosis-inducted effects of evodiamine on liver cancer cells of mice. Pharmacol Clin Chin Mater Med 22 (2006) 33-35
26. Kobayashi Y., Nakano Y., Kizaki M., Hoshikuma K., Yokoo Y., and Kamiya T. Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist. Planta Med 67 (2001) 628-633
27. Wang T., Wang Y.X., Kontani Y., Kobayashi Y., Sato Y., Mori N., et al. Evodiamine improves diet-induced obesity in a uncoupling protein-1-independent manner: involvement of antiadipogenic mechanism and extracellularly regulated kinase/mitogen-activated protein kinase signaling. Endocrinology 149 1 (2008) 358-366
28. Zhang L.L., Liu D.Y., Ma L.Q., Luo Z.D., Cao T.B., Zhong J., et al. Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ Res 100 (2007) 1063-1070
29. Pearce L.V., Petukhov P.A., Szabo T., Kedei N., Bizik F., Kozikowski A.P., et al. Evodiamine functions as an agonist for the vanilloid receptor TRPV1. Org Biomol Chem 2 (2004) 2281-2286
30. Lee Y.S., Kim W.S., Kim K.H., Yoon M.J., Cho H.J., Shen Y., et al. Berberine, a natural plant product, activates AMP activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55 (2006) 2256-2264
31. Newell F.S., Su H., Tornqvist H., Whitehead J.P., Prins J.B., and Hutley L.J. Characterization of the transcriptional and functional effects of fibroblast growth factor-1 on human preadipocyte differentiation. FASEB J 20 (2006) 2615-2617
32. Adams M., Montague C.T., Prins J.B., Holder J.C., Smith S.A., Sanders L., et al. Activators of peroxisome proliferator-activated receptor have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100 (1997) 3149-3153
33. Dos Santos E., Dieudonné M.N., Leneveu M.C., Pecquery R., Serazin V., and Giudicelli Y. In vitro effects of chorionic gonadotropin hormone on human adipose development. J Endocrinol 194 (2007) 313-325
34. Tomlinson J.J., Boudreau A., Wu D., Atlas E., and Haché R.J. Modulation of early human preadipocyte differentiation by glucocorticoids. Endocrinology 147 (2006) 5284-5293
35. Liu L.H., Wang X.K., Hu Y.D., Kang J.L., Wang L.L., and Li S. Effects of a fatty acid synthase inhibitor on adipocyte differentiation of mouse 3T3 cells. Acta Pharm Sin 25 (2004) 1052-1057
36. Furuyashiki T., Nagayasu H., Aoki Y., Bessho H., Hashimoto T., Kanazawa K., et al. Tea catichin suppresses adipocyte differentiation accompanied by down-regulation of PPARγ2 and C/EBPα in 3T3-L1 cells. Biosci Biotechnol Biochem 68 (2004) 2253-2359
37. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29 (2001) e45
38. Giri S., Rattan R., Haq E., Khan M., Yasmin R., Won J.S., et al. AICAR inhibits adipocyte differentiation in 3T3L1 and restores metabolic alterations in diet-induced obesity mice model. Nutr Metab 3 (2006) 1-20
39. Must A.J., Spadano E.H., Coakley A.E., Field A.E., Colditz G., and Dietz W.H. The disease burden associated with overweight and obesity. J Am Med Assoc 282 (1999) 1523-1529
40. Morrison R.F., and Farmer S.R. Hormonal signaling and transcriptional control of adipocyte differentiation. J Nutr 130 (2000) 3116S-3121S
41. Fox K.E., Fankell D.M., Erickson P.F., Majka S.M., Crossno Jr. J.T., and Klemm D.J. Depletion of CREB/ATF1 inhibits adipogenic conversion of 3T3-L1 cells ectopically expressing CCAAT/enhancer-binding protein (C/EBP) alpha, C/EBP beta, or PPAR gamma 2. J Biol Chem 281 (2006) 40341-40353
42. Tong Q., Tsai J., and Hotamisligil G.S. GATA transcription factors and fat cell formation. Drug News Perspect 16 (2003) 585-588
43. El Hadri K., Glorian M., Monsempes C., Dieudonné M.N., Pecquery R., Giudicelli Y., et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor Efavirenz in 3T3 and human preadipocyte or adipocytes. J Biol Chem 279 (2004) 15130-15141
44. Wentworth J.M., Burris T.P., and Chatterjee V.K.K. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARγ/RXR heterodimer. J Endocrinol 164 (2000) R7-R10